

## **Rosetta Genomics Files Pro Forma Financials in Connection with PersonalizeDx Acquisition**

*Affirms 2015 Pro Forma Full-Year Revenue Guidance of \$10 Million to \$12 Million*

**PRINCETON, N.J. and REHOVOT, Israel (July 8, 2015)** – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, reports that in connection with its April 2015 acquisition of CynoGen, Inc. (d/b/a PersonalizeDx), it has filed the audited financial statements of PersonalizeDx (PDX) as of and for the years ended December 31, 2014 and 2013 and pro forma financial information as of and for the year ended December 31, 2014, with the U.S. Securities and Exchange Commission. The filing on Form 6-K can be accessed at [www.sec.gov](http://www.sec.gov) and on the Company's website at [www.rosettagenomics.com](http://www.rosettagenomics.com).

"Completing the pro forma financials is an important part of integrating the PDX business into Rosetta," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "PDX is an excellent strategic and cultural fit that enhances and expands our commercial and revenue scale in the marketplace for oncology diagnostics. With the addition of the numerous assays from PDX, we are now positioned to be a leading company in both the broad, solid tumor diagnostics space by offering a complete suite of assays consisting of targeted NGS mutational analysis, best-in-class tumor origin confirmation/identification and best-in-class FISH and other testing for relevant tumor types, and the urologic cancer space with a broad offering of assays covering prostate, bladder and kidney cancer."

In the filings made today, revenues for PDX in 2014 were \$6.55 million, which were nearly 4-times the revenues of \$1.652 million for PDX in 2013. In addition, Rosetta Genomics reported pro forma revenue for the year ended December 31, 2014 of \$7.88 million.

Rosetta Genomics affirms its 2015 pro forma full-year revenue projection of between \$10 million to \$12 million.

In addition, the Company reports that it plans to file its financial results for the six months ended June 30, 2015 within the allotted 90-day timeframe required for foreign filers. Thereafter, Rosetta Genomics expects to report its financial results on a quarterly basis starting with the three and nine months ending September 30, 2015.

### **About Rosetta Genomics**

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the

Company offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta's and PersonalizeDx's cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit [www.rosettagenomics.com](http://www.rosettagenomics.com).

**Forward-Looking Statement Disclaimer**

Various statements in this release concerning Rosetta's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

**Company Contacts:**

Rosetta Genomics  
Ken Berlin, President & CEO  
(609) 419-9003  
[investors@rosettagenomics.com](mailto:investors@rosettagenomics.com)

**Investor Contacts:**

LHA  
Anne Marie Fields  
(212) 838-3777  
[afields@lhai.com](mailto:afields@lhai.com)  
or  
Bruce Voss  
(310) 691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)

###